Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of “Reduce” from Analysts

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have received an average recommendation of “Reduce” from the eight analysts that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $22.00.

A number of analysts have commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Wells Fargo & Company lifted their target price on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a research report on Friday. Piper Sandler decreased their price target on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Friday. Jefferies Financial Group reissued a “hold” rating and issued a $22.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Zacks Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st.

Institutional Trading of Amphastar Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Quarry LP bought a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at about $32,000. Farther Finance Advisors LLC boosted its holdings in Amphastar Pharmaceuticals by 46.3% during the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock worth $37,000 after purchasing an additional 437 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Amphastar Pharmaceuticals by 24.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock worth $60,000 after purchasing an additional 435 shares in the last quarter. TD Private Client Wealth LLC grew its position in Amphastar Pharmaceuticals by 410.1% in the 4th quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock worth $65,000 after purchasing an additional 1,944 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Amphastar Pharmaceuticals by 263.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,583 shares of the company’s stock valued at $82,000 after buying an additional 2,596 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 2.3%

Shares of NASDAQ AMPH opened at $20.31 on Tuesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.40 and a quick ratio of 1.71. The company has a 50-day moving average price of $19.70 and a 200-day moving average price of $21.32. The stock has a market capitalization of $863.99 million, a P/E ratio of 12.02, a P/E/G ratio of 4.39 and a beta of 0.89. Amphastar Pharmaceuticals has a 1 year low of $16.65 and a 1 year high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, August 6th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The company had revenue of $183.90 million for the quarter, compared to analyst estimates of $179.92 million. On average, equities research analysts forecast that Amphastar Pharmaceuticals will post 2.25 EPS for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.